Please use this identifier to cite or link to this item:
|Title:||Molecular and pharmacological evidence for modulation of kinin B-1 receptor expression by endogenous glucocorticoids hormones in rats|
|Authors:||Cabrini, Daniela A.|
Campos, Maria M.
Tratsk, Karla S.
Merino, Vanessa F.
Silva Junior, José Antonio [UNIFESP]
Souza, Glória EP
Avellar, Maria Christina Werneck [UNIFESP]
Pesquero, João Bosco [UNIFESP]
Calixto, João B.
Universidade Federal de Santa Catarina (UFSC)
Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
nuclear factor-kappa B
B-1-kinin receptor up-regulation
rat paw oedema
rat portal vein
ribonuclease protection assay
gel shift assay
|Publisher:||Nature Publishing Group|
|Citation:||British Journal of Pharmacology. Basingstoke: Nature Publishing Group, v. 132, n. 2, p. 567-577, 2001.|
|Abstract:||1 the effect of endogenous glucocorticoid hormones on the expression of rat BI receptors was examined by means of molecular and pharmacological functional approaches.2 Rats were adrenalectomized (ADX), and 7 days after this procedure the intradermal injection of B-1 receptor agonist des-Arg(9)-BK produced a significant increase in the paw volume, while only a weak effect was observed in sham-operated animals. A similar increase in the contractile responses mediated by B-1 agonist des-Arg(9)-BK was also observed in the rat portal vein in vitro.3 Chemical ADX performed with mitotane (a drug that reduces corticosteroid synthesis) produced essentially the same up-regulation of B-1 receptors as that observed in ADX rats.4 the modulation of B-1 receptor expression was evaluated by ribonuclease protection assay. employing mRNA obtained from the lungs and paw of ADX rats.5 Additionally. both paw oedema and contraction of portal vein mediated by B-1 agonist des-Arg(9)-BK in ADX mts, were markedly inhibited by treatment with dexamethasone, or COX-2 inhibitor meloxican. or with the NF-kappaB inhibitor PDTC. Interestingly, the same degree of inhibition was achieved when the animals were treated with a combination of submaximal doses of dexamethasone and PDTC.6 the involvement of NF-kappaB pathway was further confirmed by mobility shift assay using nuclear extracts from lung, paw and heart of ADX rats. It was also confirmed that the treatment of ADX rats with dexamethasone. PDTC or dexamethasone plus PDTC completely inhibit NF-kappaB activation caused by absence of endogenous glucucorticoid.7 Together. the results or the present study provide, for the first rime, molecular and pharmacological evidence showing that B-1 kinin receptor expression can be regulated through endogenous glucocorticoids by a mechanism dependent on NF-kappaB pathway. Clinical significance of the present findings stem from evidence showing the importance of B-1 kinin receptors in the mediation of inflammatory and pain related responses.|
|Appears in Collections:||Artigo|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.